SPH3127

DRUG3 trials

Sponsors

Shanghai Pharmaceuticals Holding Co., Ltd, Shanghai Pharma Biotherapeutics USA Inc.

Conditions

HypertensionPrimary Mild and Moderate HypertensionUlcerative Colitis

Phase 1

Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers

CompletedNCT03128138

Shanghai Pharmaceuticals Holding Co., LtdHypertension

Start: 2016-12-01End: 2018-07-30Updated: 2022-10-27

Study on Human Mass Balance of SPH3127 Tablets

CompletedNCT05593562

Shanghai Pharmaceuticals Holding Co., LtdPrimary Mild and Moderate Hypertension

Start: 2022-10-16End: 2022-10-24Updated: 2022-12-07

Phase 2

Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

TerminatedNCT05019742

Shanghai Pharma Biotherapeutics USA Inc.Ulcerative Colitis

Start: 2022-03-21End: 2022-11-01Updated: 2025-06-26

Related Papers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial.

2021-02-272 citations